• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4625220)   Today's Articles (760)   Subscriber (49499)
For: Carella AM. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia. Expert Rev Anticancer Ther 2007;7:249-51. [PMID: 17338645 DOI: 10.1586/14737140.7.3.249] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Number Cited by Other Article(s)
1
Wang C, Bai X, Wang R, Zheng X, Ma X, Chen H, Ai Y, Bai Y, Liu Y. Synthesis of Imatinib by C–N Coupling Reaction of Primary Amide and Bromo-Substituted Pyrimidine Amine. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00227] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
2
Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients. J Genet 2018. [DOI: 10.1007/s12041-018-0978-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA